Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.

López-Campos, José LuisFernández-Villar, AlbertoRuano-Ravina, Alberto2023-02-092023-02-092021http://hdl.handle.net/10668/16973enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AdultAgedAged, 80 and overBronchodilator AgentsBudesonideDrug CombinationsFemaleFormoterol FumarateGlycopyrrolateHumansMaleMiddle AgedPulmonary Disease, Chronic ObstructiveTreatment OutcomeTriple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.research article33444512open access10.1164/rccm.202012-4386LE1535-4970PMC8017588https://doi.org/10.1164/rccm.202012-4386lehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017588/pdf